Literature DB >> 16799335

Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.

Yangbing Zhao1, Zhili Zheng, Hung T Khong, Steven A Rosenberg, Richard A Morgan.   

Abstract

cDNAs encoding functional T cell receptor (TCR) alpha and beta chains from a CD4+ T cell line (SG6) generated by repeated stimulation of a melanoma patient's peripheral blood mononuclear cells with HLA-DP4-restricted, NY-ESO-1-specific peptide p161-180 were cloned using a 5'rapid amplification of cDNA end method. Three different TCR alpha chains and 7 TCR beta chains were found among the 84 alpha and 162 beta cDNA clones tested. By screening different combination of the alpha/beta chains using RNA electroporation, TRAV9-1 (Valpha22.1) and TRBV20-1 (Vbeta2) were found to be the functional pair in line SG6. Antibody blocking experiments confirmed that the specificity of TRAV9-1/TRBV20-1 mRNA-transfected T cells were CD4 dependent and HLA-DP4 restricted. A retroviral vector expressing both TRAV9-1 and TRBV20-1 was constructed and used for transduction of OKT3-stimulated peripheral blood lymphocytes from melanoma patients. TCR-transduced CD4 T cells were capable of recognizing peptide-pulsed antigen-presenting cells (Epstein-Barr virus transformed B-cells, dendritic cells, and peripheral blood mononuclear cells), and protein-pulsed dendritic cells. Transduced cells were also capable of proliferation upon peptide stimulation and recognized peptide concentrations that were recognized by the parental line (0.2 microM). In contrast to SG6, which could not recognize human tumors, TCR-transduced CD4 T cells could specifically recognize NY-ESO-1/HLA-DP4-expressing melanoma cells. Major histocompatibility complex class II TCR-transduced CD4 T cells provides an alternative source of tumor antigen-specific T cells for adoptive immunotherapy of cancer patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799335      PMCID: PMC1510955          DOI: 10.1097/01.cji.0000203082.20365.7f

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  54 in total

1.  Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II.

Authors:  Anna E Lokshin; Pawel Kalinski; R Rita Sassi; Robbie B Mailliard; Jan Müller-Berghaus; Walter J Storkus; Xiaojun Peng; Adele M Marrangoni; Robert P Edwards; Elieser Gorelik
Journal:  Int Immunol       Date:  2002-09       Impact factor: 4.823

2.  A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved.

Authors:  Birgit Alpen; Ali O Güre; Matthew J Scanlan; Lloyd J Old; Yao-Tseng Chen
Journal:  Gene       Date:  2002-09-04       Impact factor: 3.688

3.  Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.

Authors:  Steven A Rosenberg; Mark E Dudley
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-20       Impact factor: 11.205

4.  Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.

Authors:  Sacha Gnjatic; Djordje Atanackovic; Elke Jäger; Mitsutoshi Matsuo; Annamalai Selvakumar; Nasser K Altorki; Robert G Maki; Bo Dupont; Gerd Ritter; Yao-Tseng Chen; Alexander Knuth; Lloyd J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

Review 5.  The cancer/testis genes: review, standardization, and commentary.

Authors:  Matthew J Scanlan; Andrew J G Simpson; Lloyd J Old
Journal:  Cancer Immun       Date:  2004-01-23

Review 6.  Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.

Authors:  Matthew J Scanlan; Ali O Gure; Achim A Jungbluth; Lloyd J Old; Yao-Tseng Chen
Journal:  Immunol Rev       Date:  2002-10       Impact factor: 12.988

7.  High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.

Authors:  Richard A Morgan; Mark E Dudley; Yik Y L Yu; Zhili Zheng; Paul F Robbins; Marc R Theoret; John R Wunderlich; Marybeth S Hughes; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

8.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.

Authors:  François Ghiringhelli; Nicolas Larmonier; Elise Schmitt; Arnaud Parcellier; Dominique Cathelin; Carmen Garrido; Bruno Chauffert; Eric Solary; Bernard Bonnotte; François Martin
Journal:  Eur J Immunol       Date:  2004-02       Impact factor: 5.532

9.  A simple method to cure established tumors by inflammatory killing of normal cells.

Authors:  Gregory A Daniels; Luis Sanchez-Perez; Rosa Maria Diaz; Timothy Kottke; Jill Thompson; Maoyi Lai; Michael Gough; Mahzuz Karim; Andrew Bushell; Heung Chong; Alan Melcher; Kevin Harrington; Richard G Vile
Journal:  Nat Biotechnol       Date:  2004-08-01       Impact factor: 54.908

10.  CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.

Authors:  Sacha Gnjatic; Elke Jäger; Weisan Chen; Nasser K Altorki; Mitsutoshi Matsuo; Sang-Yull Lee; Qiyuan Chen; Yasuhiro Nagata; Djordje Atanackovic; Yao-Tseng Chen; Gerd Ritter; Jonathan Cebon; Alexander Knuth; Lloyd J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-19       Impact factor: 11.205

View more
  12 in total

Review 1.  Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.

Authors:  Chantale Bernatchez; Laszlo G Radvanyi; Patrick Hwu
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

2.  Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.

Authors:  Lucia Poncette; Xiaojing Chen; Felix Km Lorenz; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

3.  Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.

Authors:  Cyrille J Cohen; Yangbing Zhao; Zhili Zheng; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

4.  Selective modification of antigen-specific T cells by RNA electroporation.

Authors:  Duane A Mitchell; Isaac Karikari; Xiuyu Cui; Weihua Xie; Robert Schmittling; John H Sampson
Journal:  Hum Gene Ther       Date:  2008-05       Impact factor: 5.695

5.  Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.

Authors:  Maria R Parkhurst; Jayne Joo; John P Riley; Zhiya Yu; Yong Li; Paul F Robbins; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

6.  TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.

Authors:  Trudy Straetemans; Mandy van Brakel; Sabine van Steenbergen; Marieke Broertjes; Joost Drexhage; Joost Hegmans; Bart N Lambrecht; Cor Lamers; Pierre van Der Bruggen; Pierre G Coulie; Reno Debets
Journal:  Clin Dev Immunol       Date:  2012-02-12

7.  How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer.

Authors:  Inbal Daniel-Meshulam; Shlomo Ya'akobi; Chen Ankri; Cyrille J Cohen
Journal:  Front Immunol       Date:  2012-07-06       Impact factor: 7.561

Review 8.  The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.

Authors:  Zeming Mo; Peixin Du; Guoping Wang; Yongsheng Wang
Journal:  J Cancer       Date:  2017-06-23       Impact factor: 4.207

Review 9.  Adaptive T cell immunotherapy in cancer.

Authors:  Dongdong Ti; Miaomiao Bai; Xiaolei Li; Jianshu Wei; Deyun Chen; Zhiqiang Wu; Yao Wang; Weidong Han
Journal:  Sci China Life Sci       Date:  2020-07-23       Impact factor: 6.038

10.  The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.

Authors:  Bianca Simon; Manuel Wiesinger; Johannes März; Kilian Wistuba-Hamprecht; Benjamin Weide; Beatrice Schuler-Thurner; Gerold Schuler; Jan Dörrie; Ugur Uslu
Journal:  Int J Mol Sci       Date:  2018-08-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.